Paul Kim

All filings by Paul Kim on record concern Fulgent Genetics, Inc., in the capacity of finance chief. In total, 114 filings cover trades dated from 11 August 2017 to 1 September 2026.

The open-market side counts 1 purchase for €1.5M alongside 49 sales for €14.2M. On balance, insiders were net sellers of €12.7M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 62 share grants.

The latest filing, published on 3 September 2026, reports a share grant of €35k in Fulgent Genetics, Inc. The last purchase on record was published on 5 March 2025, which is 597 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.